Entyvio Eased Early Symptoms of Ulcerative Colitis and Crohn’s, New Analysis Shows

Entyvio Eased Early Symptoms of Ulcerative Colitis and Crohn’s, New Analysis Shows
Entyvio (vedolizumab) alleviated some of the early symptoms of patients with moderate to severe ulcerative colitis and Crohn's disease, a new analysis of Phase 3 trial results indicates. Takeda Pharmaceutical presented the additional findings of the GEMINI clinical trial program, which covered 2,400 patients, at the World Congress of Gastroenterology in Orlando, Oct. 13-18. Two ulcerative colitis improvements that one poster presentation focused on were less rectal bleeding and fewer trips to the toilet to defecate — both indicators of remission. The title of the presentation was “Vedolizumab Demonstrates Early Symptomatic Improvement in Ulcerative Colitis: A GEMINI 1 Post hoc Analysis.” Researchers randomly assigned patients with active ulcerative colitis to receive either Entyvio or a placebo at the start of the six-week trial and in the second week. The team assessed patients' rectal bleeding and stool frequency at the start of the study and weeks 2, 4, and 6. They used Mayo Clinic rating scales for the symptoms. The team paid particular attention to the symptoms in patients who had not been treated with a tumor necrosis factor antagonist. A TNF antagonist prevents the cytokine TNF from promoting inflammation and pain. There was less rectal bleeding and stool frequency among Entyvio-treated patients than in the placebo group, researchers reported. The most significant improvements were seen in those who had never been treated w
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *